Discover 1,461 paid clinical trials in Tacoma, Washington. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Location: Seattle WA, Kansas City KS, Park Ridge IL, Buffalo NY,
Sponsor: Cerus Endovascular, Inc.
Sex: All
Age: 18 - 70+
Code: NCT06693011
Recruiting
Active & Responsive
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
for
Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
Location: Seattle WA, Redwood City CA, Orange CA, Kansas City MO,
Sponsor: Bleeding and Clotting Disorders Institute Peoria, Illinois
Sex: All
Age: 0 - 70+
Code: NCT05500807
Phase 1, Recruiting
Active & Responsive
Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care
for
Arthritis, Rheumatoid
Location: Seattle WA, Bothell WA, Spokane WA, Covina CA,
Sponsor: Crescendo Bioscience
Sex: All
Age: 18 - 70+
Code: NCT02832297
Recruiting
Active & Responsive
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
for
Healthy
Location: Seattle WA, Garden City ID, Boise ID, Missoula MT,
Sponsor: Pfizer
Sex: All
Age: 0 - 49
Code: NCT07160244
Phase 3, Recruiting
Active & Responsive
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
for
Type 1 Diabetes Mellitus With Hypoglycemia
Location: Seattle WA, Vancouver, Calgary, Sandy City UT,
Sponsor: Zucara Therapeutics Inc.
Sex: All
Age: 18 - 70+
Code: NCT05762107
Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
for
Metastatic Castration-Resistant Prostate Cancer
Location: Seattle WA, Portland OR, San Francisco CA,
Sponsor: Zenith Epigenetics
Sex: Male
Age: 18+
Code: NCT04986423
Phase 2, Recruiting
Active & Responsive
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
for
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver,
Location: Seattle WA, Portland OR, San Francisco CA, Billings MT,
Sponsor: Massive Bio, Inc.
Sex: All
Age: 0+
Code: NCT03452774
Recruiting
Active & Responsive
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Location: Seattle WA, Los Angeles CA, La Jolla CA, Gilbert AZ,
Sponsor: A2 Biotherapeutics Inc.
Sex: All
Age: 18+
Code: NCT06682793
Phase 1, Phase 2, Recruiting
Active & Responsive
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
for
Prostate Carcinoma
Location: Seattle WA, Portland OR, San Francisco CA, Duarte CA,
Sponsor: University of Washington
Sex: Male
Age: 40+
Code: NCT04472338
Recruiting
Active & Responsive
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
for
Castration-Resistant Prostate Carcinoma,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center
Sex: Male
Age: 0+
Code: NCT06145633
Phase 2, Recruiting
Active & Responsive
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
for
Solid Tumor, Adult, Colorectal Cancer,
Location: Seattle WA, Palo Alto CA, Santa Monica CA, La Jolla CA,
Sponsor: A2 Biotherapeutics Inc.
Sex: All
Age: 18+
Code: NCT04981119
Recruiting
Active & Responsive
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
for
Solid Tumor, Adult, Colorectal Cancer, NSCLC,
Location: Seattle WA, Stanford CA, Los Angeles CA, La Jolla CA,
Sponsor: A2 Biotherapeutics Inc.
Sex: All
Age: 18+
Code: NCT06051695
Phase 1, Phase 2, Recruiting
Active & Responsive
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
for
HER2-positive Metastatic Breast Cancer
Location: Seattle WA, San Francisco CA, New Lenox IL,
Sponsor: Abramson Cancer Center at Penn Medicine
Sex: All
Age: 18+
Code: NCT06551116
Recruiting
Active & Responsive
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
for
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Location: Seattle WA, St Louis MO, Pittsburgh PA
Sponsor: Sawa Ito, MD
Sex: All
Age: 18+
Code: NCT06529731
Phase 2, Recruiting
Active & Responsive
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
for
Localized Renal Pelvis and Ureter Urothelial Carcinoma,
Location: Seattle WA
Sponsor: University of Washington
Sex: Male
Age: 18+
Code: NCT01050504
Recruiting
Active & Responsive
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
for
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL),
Location: Seattle WA, Duarte CA, Omaha NE, St Louis MO,
Sponsor: Umoja Biopharma
Sex: All
Age: 18+
Code: NCT06528301
Phase 1, Recruiting
Active & Responsive
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Location: Seattle WA, Duarte CA, Minneapolis MN, New York NY,
Sponsor: Tr1X, Inc.
Sex: All
Age: 18+
Code: NCT06462365
Phase 1, Recruiting
Active & Responsive
[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma
for
Cholangiocarcinoma
Location: Seattle WA
Sponsor: University of Washington
Sex: All
Age: 18+
Code: NCT07673341
Phase 2, Recruiting
Active & Responsive
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial